Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

22.33B

Market cap22.33B

Price-Earnings ratio

14.34

Price-Earnings ratio14.34

Dividend yield

—

Dividend yield—

Average volume

1.24M

Average volume1.24M

High today

$151.91

High today$151.91

Low today

$148.98

Low today$148.98

Open price

$150.97

Open price$150.97

Volume

1.30M

Volume1.30M

52 Week high

$187.58

52 Week high$187.58

52 Week low

$110.04

52 Week low$110.04

BIIB News

Simply Wall St 10h

Does Biogen’s Vanqua Deal and SLE Data Reinforce Its Long-Term Immunology Strategy?

In the past week, Biogen Inc. announced it has gained exclusive worldwide rights to Vanqua Bio’s preclinical oral C5aR1 antagonist in a deal potentially worth o...

Benzinga 2d

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1...

Nasdaq 2d

Biogen Inks License Deal For Vanqua Bio's Oral C5aR1 Antagonist

(RTTNews) - Biogen Inc. (BIIB), Friday announced a license agreement granting the company exclusive worldwide rights to Chicago-based Vanqua Bio's preclinical,...

Analyst ratings

51%

of 37 ratings

Buy

48.6%

Hold

51.4%

Sell

More BIIB News

TipRanks 2d

Biogen licenses oral C5aR1 antagonist from Vanqua Bio

Biogen (BIIB) and Vanqua announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. Under the term...

Simply Wall St 4d

Biogen Valuation in Focus After New Dravet Syndrome Data Shows Extended Clinical Benefit

Biogen (BIIB) shares are in focus after new clinical data showed extended improvements for Dravet syndrome patients taking zorevunersen. The findings, presented...

TipRanks 4d

Biogen to present additional results from Phase 3 study of dapirolizumab pegol

Biogen (BIIB) announced upcoming presentations from studies evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in systemic lupus erythem...

TipRanks 6d

Biogen’s Hold Rating Justified by Limited Growth Prospects and Pipeline Uncertainty

Tim Anderson, an analyst from Bank of America Securities, reiterated the Hold rating on Biogen. The associated price target remains the same with $167.00. Eleva...

The Motley Fool 7d

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround

Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen (BIIB 0.58%) during the third quarter for an estimated $16.1 million. What H...

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.